Absci's quality metrics sit well below the engine's investable floor, with heavy cash burn, a negative risk/reward setup, and no clear technical edge, even as a supportive analyst mention and light insider buying provide the only offsetting signals.
Thesis pillars
- Quality Below Investable Floor→Stable
- Negative Asymmetry At Target→Stable
- No Edge Speculative Sizing Cap→Stable
- +2 more pillars — see the Why tab for full reasoning
Absci Corporation (ABSI) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $11.85: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 27%; Elevated put/call ratio: 3.44; Below-average business quality.
Absci is a clinical-stage, AI-native biopharmaceutical company that designs antibody therapeutics using its Integrated Drug Creation platform, combining a generative AI model (Origin-1) with rapid wet-lab validation. Its lead internal candidate, ABS-201, targets the prolactin... Read more
Sell if holding. Engine safety override at $11.85: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 27%; Elevated put/call ratio: 3.44; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.2/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.50, earnings proximity 40d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Absci Corporation
About Absci Corporation
Absci's lead internally developed candidate, ABS-201, entered the Phase 1/2a HEADLINE clinical trial in December 2025 targeting androgenetic alopecia, a condition affecting an estimated 80 million people in the United States, with interim proof-of-concept data expected in the second half of 2026 and a Phase 2 endometriosis trial planned for the fourth quarter of 2026. The company held $144.3 million in cash, cash equivalents and marketable securities as of December 31, 2025, against a $115.2 million net loss for the year.
Absci earns revenue primarily from drug-creation collaborations, in which pharmaceutical partners pay upfront and research fees plus technical-milestone payments while Absci's Integrated Drug Creation platform designs antibody candidates against partner-selected targets; the company has a track record of partnerships with Merck, AstraZeneca, Almirall and others, though as of March 24, 2026 no partner had yet entered a license for clinical or commercial use of any resulting intellectual property. Substantially all of Absci's historical revenue has come from these partnered drug-creation activities rather than from royalties or milestones tied to an approved product. Internally, the company also advances five wholly-owned programs including ABS-201, and previously advanced ABS-101 through Phase 1 before choosing in November 2025 to seek an outside partner rather than fund later-stage development itself, reflecting a capital-efficient strategy of partnering or out-licensing programs once they reach a value inflection point.
Show full overview
Because substantially all of Absci's historical revenue has come from partnered drug-creation fees rather than milestone or royalty payments, the company's near-term financial trajectory remains tied to specific binary events: no partner had signed a commercial or clinical license as of March 24, 2026, and interim proof-of-concept data for ABS-201 in androgenetic alopecia is not expected until the second half of 2026, with full data in early 2027. A negative readout or a partner's decision to terminate a drug-creation agreement before reaching the licensing stage would leave Absci without the downstream royalty economics its business model is designed to capture.
See also: Healthcare · Biotechnology
From Absci Corporation's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-06Recent Developments — Absci Corporation
Latest news
- NEWS Truist Securities Maintains Buy on Absci, Raises Price Target to $17 — benzinga Jul 2, 2026 positive
- NEWS Anthropic Is Going All In on Drug Discovery Just as Pharma Stops Talking About AI — benzinga Jul 1, 2026 neutral
Generated 2026-07-07T11:21:37Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerpartnered drug creation programs10-K Item 1A: 'For the year ended December 31, 2025, all of our revenue was generated by performing drug creation activities for our partnered programs.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 10.2% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $11.85: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 27%; Elevated put/call ratio: 3.44; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $10.81. Score 4.2/10, moderate confidence.
Take-profit target: $11.81 (+1.6% upside). Prior stop was $10.81. Stop-loss: $10.81.
Concentration risk — Customer: partnered drug creation programs; Target reached (-2.7% upside); Quality below floor (1.4 < 4.0).
Absci Corporation trades at a P/E of N/A (forward -18.6). TrendMatrix value score: 4.0/10. Verdict: Sell.
16 analysts cover ABSI with a consensus score of 4.1/5. Average price target: $13.
What does Absci Corporation do?Absci is a clinical-stage, AI-native biopharmaceutical company that designs antibody therapeutics using its Integrated...
Absci is a clinical-stage, AI-native biopharmaceutical company that designs antibody therapeutics using its Integrated Drug Creation platform, combining a generative AI model (Origin-1) with rapid wet-lab validation. Its lead internal candidate, ABS-201, targets the prolactin receptor for androgenetic alopecia and endometriosis and is in an ongoing Phase 1/2a trial, while nearly all of the company's historical revenue has come from drug-creation partnerships with companies including Merck, AstraZeneca and Almirall.